Insider Selling: Axon Enterprise (NASDAQ:AXON) President Sells $11,879,712.94 in Stock

Key Points

• Joshua Isner, President of Axon Enterprise, sold 15,919 shares of stock for a total of approximately $11.88 million, reducing his ownership by 6.26% to 238,379 shares valued at about $177.89 million.
• Axon Enterprise's stock is currently trading at $754.24, showing a slight increase of 0.6%, with analysts predicting an average target price of $837.69 for the future.
• Recent earnings report indicated an EPS of $2.12, surpassing expectations and showing a year-over-year revenue growth of 32.6%.

Axon Enterprise, Inc (NASDAQ:AXON - Get Free Report) President Joshua Isner sold 15,919 shares of the firm's stock in a transaction on Friday, August 15th. The stock was sold at an average price of $746.26, for a total value of $11,879,712.94. Following the sale, the president directly owned 238,379 shares of the company's stock, valued at approximately $177,892,712.54. This represents a 6.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Joshua Isner also recently made the following trade(s):

• On Tuesday, June 17th, Joshua Isner sold 905 shares of Axon Enterprise stock. The stock was sold at an average price of $776.39, for a total value of $702,632.95.
• On Wednesday, May 21st, Joshua Isner sold 9,905 shares of Axon Enterprise stock. The shares were sold at an average price of $738.03, for a total value of $7,310,187.15.

Axon Enterprise Trading Up 0.3%

AXON traded up $2.60 during trading on Wednesday, reaching $760.89. The company had a trading volume of 409,636 shares, compared to its average volume of 811,097. The firm's 50-day simple moving average is $773.57 and its 200 day simple moving average is $672.61. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. The company has a market cap of $59.73 billion, a price-to-earnings ratio of 187.87, a PEG ratio of 27.83 and a beta of 1.36. Axon Enterprise, Inc has a 12-month low of $346.71 and a 12-month high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.58. The company had revenue of $668.54 million during the quarter, compared to analyst estimates of $641.77 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. The business's quarterly revenue was up 32.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have weighed in on the stock. UBS Group reiterated a "neutral" rating and set a $840.00 price objective (up from $820.00) on shares of Axon Enterprise in a research report on Tuesday, August 5th. Wolfe Research initiated coverage on Axon Enterprise in a report on Monday, July 7th. They set an "outperform" rating on the stock. Morgan Stanley set a $885.00 price target on Axon Enterprise and gave the company an "overweight" rating in a research report on Friday, July 11th. JPMorgan Chase & Co. raised their price objective on Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a research report on Thursday, July 17th. Finally, Craig Hallum raised Axon Enterprise from a "hold" rating to a "buy" rating and set a $900.00 target price on the stock in a research note on Tuesday, August 5th. Thirteen analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, Axon Enterprise has a consensus rating of "Moderate Buy" and a consensus target price of $837.69.

Institutional Trading of Axon Enterprise

Institutional investors have recently bought and sold shares of the company. Westside Investment Management Inc. grew its stake in shares of Axon Enterprise by 4.8% during the second quarter. Westside Investment Management Inc. now owns 283 shares of the biotechnology company's stock valued at $225,000 after purchasing an additional 13 shares during the last quarter. CVA Family Office LLC lifted its holdings in Axon Enterprise by 26.9% during the 2nd quarter. CVA Family Office LLC now owns 66 shares of the biotechnology company's stock worth $55,000 after buying an additional 14 shares in the last quarter. Newbridge Financial Services Group Inc. boosted its position in Axon Enterprise by 2.8% in the 2nd quarter. Newbridge Financial Services Group Inc. now owns 508 shares of the biotechnology company's stock valued at $421,000 after buying an additional 14 shares during the last quarter. Evergreen Capital Management LLC boosted its position in Axon Enterprise by 3.8% in the 2nd quarter. Evergreen Capital Management LLC now owns 413 shares of the biotechnology company's stock valued at $342,000 after buying an additional 15 shares during the last quarter. Finally, LaSalle St. Investment Advisors LLC increased its stake in shares of Axon Enterprise by 2.1% in the 1st quarter. LaSalle St. Investment Advisors LLC now owns 777 shares of the biotechnology company's stock valued at $408,000 after buying an additional 16 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.